Abstract
Approximately 30% of all pancreatic cancer patients have locally advanced (AJCC stage 3) disease. A sub-group of these patients—where the cancer only involves the celiac axis—may benefit from distal pancreatectomy with celiac axis resection (DP-CAR). Previous studies have shown that DP-CAR offers a survival benefit to a selected group of patients with otherwise unresectable pancreatic cancer, when performed by experienced pancreatic cancer treatment teams at high-volume centers. This article proposes a standardized approach to DP-CAR, including routine neoadjuvant (FOLFIRINOX) chemotherapy. This approach to selecting patients and performing DP-CAR has the potential to improve short-term outcomes and overall survival in selected patients, but it should be reserved for high-volume centers.
Original language | English (US) |
---|---|
Pages (from-to) | 1804-1810 |
Number of pages | 7 |
Journal | Journal of Gastrointestinal Surgery |
Volume | 22 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2018 |
Keywords
- Appleby
- Cancer
- DP-CAR
- High volume
- Ischemia
- Morbidity
- Mortality
- Pancreas
- Pancreas surgery
- Pancreatic cancer
- Pancreatic fistula
- Survival
- Technique
ASJC Scopus subject areas
- Surgery
- Gastroenterology